Body System
Roche and Alnylam Push Zilebesiran into Phase III Trial Despite Mixed Phase II Hypertension Data
Roche; Alnylam; zilebesiran; hypertension; RNAi therapeutics; KARDIA-3; Phase II trial; Phase III trial; cardiovascular outcomes; ZENITH trial
Lilly’s Mounjaro Matches Cardiovascular Benefit of Trulicity in Landmark Trial, Paving Way for Expanded Approval
Mounjaro; tirzepatide; Eli Lilly; cardiovascular outcomes; type 2 diabetes; SURPASS-CVOT; Trulicity; dulaglutide; major adverse cardiovascular events (MACE-3); non-inferiority; A1C reduction; weight loss; mortality; FDA expansion
Tourmaline Bio’s Heart Drug Pacibekitug Shows Promise Against Cardiovascular Inflammation, Targets Competition with Novo, CSL
Tourmaline Bio; heart drug; pacibekitug; cardiovascular inflammation; inflammation markers; Novo Nordisk; CSL; Phase 2 trial; FDA; IL-6
FDA clears Exelixis’ TKI for neuroendocrine tumours
CABOMETYX, cabozantinib, neuroendocrine tumors, FDA approval, Exelixis, tyrosine kinase inhibitor
ITM Reports Positive Phase 3 Data for Radiopharmaceutical ITM-11 in Neuroendocrine Tumors, Challenging Novartis’ Lutathera
ITM-11, radiopharmaceutical, Phase 3 COMPETE trial, neuroendocrine tumors, Lutathera, Novartis
Heartbeat Chronicles: Inspiring Stories and Breakthroughs in Cardiovascular Health
Heart disease, patient stories, medical advancements, cardiac research, heart health, cardiovascular breakthroughs
ITM’s Radiopharmaceutical ITM-11 Shows Promising Results in Phase III COMPOSE Trial for Advanced Neuroendocrine Tumors
ITM-11, neuroendocrine tumors, GEP-NETs, COMPOSE trial, targeted radionuclide therapy, 177Lu-edotreotide
Takeda to Discontinue Uloric: A Gradual Decline of the Gout Medication
Takeda, Uloric, gout medication, discontinuation, cardiovascular risks, FDA scrutiny
SiteOne Therapeutics Secures $100M Series C Funding to Advance Non-Opioid Pain Treatments
Non-opioid pain treatments, SiteOne Therapeutics, Series C funding, ion channel modulators, peripheral nervous system (PNS), sensory hyperexcitability disorders.
Novo Holdings Spearheads $100M Series C Financing for SiteOne Therapeutics to Develop Non-Opioid Pain Therapies
Novo Holdings, SiteOne Therapeutics, Non-opioid pain treatments, Series C financing, Ion channel modulators, Peripheral nervous system (PNS) pain treatments, Chronic pain management, Opioid epidemic